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Abstract
The abscopal effect of radiation describes tumor regression in metastases outside of the field upon treatment of
one site, and is mediated by radiation-induced anti-tumor T cells. The ability of radiation to generate an in situ
tumor vaccine and improve responses to immunotherapy is under intense investigation in the clinic. Preclinical and
clinical evidence shows that multiple factors regulate radiation interaction with the immune system within and
outside of the irradiated tumor. Poleszczuk and colleagues developed a mathematical model of T cell trafficking
between metastases, and in a recent publication propose that the specific metastatic site irradiated determines the
ability of T cells to traffic to other metastases and mediate abscopal responses and should dictate clinical decision
making [Poleszczuk et al. Cancer Res 76:1009-18, 2016]. Here we critically discuss this model in light of the currently
available information about abscopal responses in mice and patients. Caution in relying upon overly simplified
models, before validation in real patients, is recommended.
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Text
The term “abscopal effect” has been used for over sixty
years to describe the rare occurrence of tumor regres-
sion in metastases away from the irradiated target lesion,
hence “ab scopus” which in Latin means outside of the
target [1]. Twelve years ago we linked the abscopal effect
to immunity, when we demonstrated an out of field re-
sponse in a syngeneic murine model of mammary car-
cinoma treated by localized radiation and FMS-like
tyrosine kinase 3 ligand (Flt-3L), that was abrogated in
similar experiments performed in nude mice [2]. In re-
cent years, the term has gained popularity due to reports
of abscopal responses in melanoma patients treated with
local radiotherapy while they were progressing during
treatment with anti-CTLA-4 antibody [3]. Evidence that
the abscopal effect is mediated by radiation-induced
anti-tumor T cells, and can be induced in mice and pa-
tients by combining local radiation with growth factors
for dendritic cells, Toll Like Receptor (TLR) agonists or
immune checkpoint inhibitors, has opened a new field
of investigation [2, 4–7]. Close to hundred trials are on-
going, to test the ability of local radiotherapy to induce
an in situ tumor vaccine and enhance systemic re-
sponses to immune checkpoint inhibitors in cancer pa-
tients, or to test the combination of radiation with a
variety of other immune modulators (clinicaltrials.gov).
Several questions remain unanswered about the opti-
mal use of radiation to convert the irradiated tumor into
an in situ vaccine and achieve abscopal responses, in-
cluding the dose, schedule and technique of radiation,
the sequencing with different immune modulators, and
the susceptibility of different tumor types and carriers
[8]. An intriguing question is whether the location of the
tumor that is irradiated contributes to the likelihood of
inducing abscopal responses. In a recently published art-
icle Jan Poleszczuk and colleagues have generated a
mathematical model to predict the answer to this ques-
tion [9]. To build the model they hypothesized that
abscopal responses can only be achieved if T cells acti-
vated at one tumor site reach each of the other metasta-
ses in sufficient numbers. In addition, they made the
assumption that trafficking of the activated T cells from
the site of activation (the irradiated tumor) to a given
organ containing metastases will be determined by the
physiologic blood flow to that organ, and by the initial im-
printing of the T cells by tumor antigen-presenting den-
dritic cells, which confer tissue-tropism to the primed T
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cells. Using these parameters they calculated the
“immunogenicity index” of metastatic sites in virtual pa-
tients. They propose that their model can be applied to
identify treatment targets with the highest likelihood of in-
ducing abscopal effects, which are patient-specific and not
otherwise intuitively predictable.
The limitations of the model stem from its virtual
foundations. Instead of generating an annotated registry
of abscopal reponders [3, 7] and interrogating such a
database to design the model, the authors have gener-
ated an “in silico” set of 40 virtual “patients”, to model
their theory of T cell trafficking and homing. The limita-
tions are more evident when the model is confronted
with the abscopal effects of radiotherapy in real patients:
clinical out of the field responses occur over a period of
months, suggesting that the speed or efficiency of initial
trafficking from the irradiated tumor and/or tumor-
draining lymph nodes where the priming occurred may
not be a critical factor [3, 6, 7]. Rather, immunogenic cell
death induced by radiation is a gradual process, evolving
beyond the completion of radiation treatment. Factors
that favor or hinder local proliferation and expansion of
the anti-tumor T cells at a given metastatic site are more
likely to be critical determinants of the abscopal re-
sponse. For instance the common expression of anti-
gen(s) or neoantigens between the irradiated metastasis
and other tumor sites may be key to an abscopal re-
sponse. In our experience abscopal reponses in patients
were metachronous, with each metastasis regressing at
different times [6, 7]. Thus, rejection of a tumor at one
abscopal site can prime new T cells or expand the T cell
originally primed at the irradiated site, generating a T
cell response that is broader not only in number of ef-
fector T cells, but also in their antigenic specificity and
tissue tropism.
Another fundamental parameter that is missing in the
model relates to the effect of the specific radiotherapy
used to trigger an abscopal response. Both the dose and
fractionation regimen as well as the target volume chosen
directly impact adequacy of naïve T cells indispensible for
successful immunization. In a model of a classical 8 cm
diameter target, treated with the classical 30 fractions of
2 Gy each of standard radiotherapy, 99 % of the circulat-
ing blood cells were likely to receive >0.5 Gy, a dose suffi-
cient to markedly reduce the number of available naïve T
cells at the time of cross presentation [10].
Overall, it is possible that the specific location of the ir-
radiated metastasis may influence the chances for gener-
ation of an in situ vaccine by radiation. However, we
reckon that the local immune microenvironment, and
especially the availability of dendritic cells, which cross-
present the antigens released by radiation, and of sufficient
naïve T cells at the time of cross presentation determines
the magnitude of the anti-tumor immune responses
primed and likely trumps blood flow [2, 6]. Radiation not
only induces an immunogenic death of the cancer cells,
but enhances pro-inflammatory chemokines and vascular
adhesion molecules, as well as major histocompatibility
class I (MHC-I), natural-killer group 2, member D
(NKG2D) ligands and Fas/CD95 expression on the cancer
cells that survive, effectively converting the irradiated
tumor into an immunogenic hub, where cycles of antigen
release and cross-presentation can occur over time [8].
The degree to which each of these pro-immunogenic pro-
cesses will take place depends on the balance of the pre-
existing immunosuppressive factors with the activating
and suppressive signals generated by radiation. In a meta-
static setting, radiation alone seldom shifts the balance to-
wards immune activation, as demonstrated by the rarity of
abscopal effects; however when combined with immune
modulators abscopal effects occur in approximately a
third of patients [5, 6]. In this context, the size of the
tumor chosen for radiation may play a complex role: while
presumably a larger tumor could release more antigens,
both quantitatively and qualitatively (e.g., a larger variety
of neoantigens), it is also likely to contain more areas of
hypoxia, which are both, radioresistant and highly im-
munosuppressive. Additionally, radiation targeting of lar-
ger tissue volumes, in deeper sites, exposes more
circulating naïve T cells to cytocidal doses, with conse-
quent lymphopenia [10]. Thus, overlapping sets of vari-
ables that are likely to influence clinical outcome need to
be reckoned with to develop a clinically meaningful
model.
In conclusion, more information about the determinants
of the abscopal effect is needed to guide the design of clin-
ical trials testing local radiation with the rapidly growing
number of immunotherapy agents. Mathematical modeling
is a welcome addition to the cadre of experimental ap-
proaches used to interrogate the mechanisms of the absco-
pal effect. However, the potential impact of a model is
dictated by its ability to comprehensively address the con-
tribution of multiple interrelated factors in achieving the
outcome studied, and by rigorous validation against any
available clinical information. An oversimplified model such
as the one described by Jan Poleszczuk and colleagues [9]
not only has limited usefulness, but also risks misleading
the design of clinical studies.
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